Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the "transformative deal" needed for a core generics comeback. Next year looks possible for recovery, but what of Teva's long-term revival?
More recent articles about Teva Pharmaceutical:
- Teva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral Truvada
- After Teva Pharmaceutical's Big Jump, This Analyst Remains Unenthused
- This Analyst Still Projects Over 40% Downside For Teva Pharmaceutical Industries Ltd (ADR) (TEVA); Here's Why
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Shares Took off on Back of CEO Kare Schultz's First Call Today